Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment

Completed · Phase 1

Conditions studied: Hepatic Impairment

In brief

This study is aimed to compare the pharmacokinetics of levonadifloxacin and its sulfate metabolite after a single dose of oral WCK 2349 1000 mg in patients with hepatic impairment and healthy volunteers.

Key facts

Study ID

NCT02244827

Run by

Wockhardt

People needed

48

Starts

2014-09-01

Expected to finish

2015-06-01

Last updated by the study team

2015-10-29

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Body Mass Index (BMI): 18.0 - 38.0 (Body weight in kg / Height in m2), both inclusive.
• Subjects must fulfill the following criteria:
• Patients with hepatic impairment:
• Considered clinically stable in the opinion of the Investigator
• Patients with different degrees of impaired hepatic function as assessed by a Child-Pugh classification score: mild (5-6 points), moderate (7-9 points) and severe (10-15 points) impaired hepatic function.
• Documented history of cirrhosis diagnosed by liver biopsy, ultrasonography (USG), computed tomography (CT) scan, or magnetic resonance imaging (MRI) OR
• Healthy volunteers:
• Have normal hepatic function
• Participants with a history of self-limited hepatitis A with complete resolution documented at least 6 months prior to entry will be allowed

You may not qualify if…

• Known hypersensitivity to quinolones/fluoroquinolones.
• Subjects must not fulfill the following criteria:
• In hepatically impaired patients:
• Use of prohibited concomitant medication, with the exception of those essential for the management of hepatic impairment and the treatment of concomitant stable medical conditions for the hepatically impaired patients as per the discretion of the Investigator.
• Fluctuating or rapidly deteriorating hepatic function as indicated by recent history or widely varying or worsening of clinical and/or laboratory signs of hepatic impairment as judged by the Investigator.
• Concomitant treatment with Interferon or other prohibited medications
• Active stage 3 and stage 4 encephalopathy OR
• Healthy Volunteers:
• Use of any concomitant medication within 7 days from the screening except those deemed safe for the study by the Investigator and Medical Monitor.
• History of any clinically significant chronic and/or active hepatic disease including elevations of serum transaminases including aspartate aminotransferase (AST) and alanine aminotransferase (ALT) [except those which are considered non-significant by the Investigator; however, these should not exceed 1.5 times the Upper Limit of Normal (ULN)], hepatitis (Hepatitis A, B or C), biliary tract disease, or history of any significant gastrointestinal surgery.

Where it is running

• University of Miami,Division of Clinical Pharmacology — Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.